What is BioAge Labs, Inc (BIOA) stock price today?

BioAge Labs, Inc (BIOA) currently trades at $16.85 per share. The stock has a market capitalization of $756.98M and a P/E ratio of —x.

Is BIOA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, BioAge Labs, Inc has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 5/9 and Altman Z-Score is 4.81.

What is BioAge Labs, Inc's revenue and earnings?

BioAge Labs, Inc has trailing twelve-month (TTM) revenue of $8.99M with profit margins of 0.00%. Earnings per share (EPS) is $-2.24.

Is BioAge Labs, Inc financially healthy?

BioAge Labs, Inc's Piotroski F-Score is 5/9 (moderate financial health). The Altman Z-Score of 4.81 places it in the safe zone.

BIOA

BioAge Labs, Inc

NASDAQ: BIOA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$16.85

-0.06% today

Updated 2026-04-30

Market cap

$756.98M

P/E ratio

—

P/S ratio

84.16x

EPS (TTM)

$-2.24

Dividend yield

—

52W range

$4 – $24

Volume

0.5M

Market cap

$756.98M

P/E ratio

—

P/S ratio

84.16x

EPS (TTM)

$-2.24

Dividend yield

—

52W range

$4 – $24

Volume

0.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

9.0

Quality

A+

2.5

Profitability

5.0

Valuation

C+

5/9

Piotroski F-Score

Moderate

4.8

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

$53.33

+216.50%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy3 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 4.81 — safe zone

+ Debt/equity 0.03x — low leverage

Risks

- Thin margins at 0.00%

- Negative free cash flow $-28.36M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$8.99M	$8.99M
Net income	$-39.72M	$-63.85M	$-71.11M	$-80.61M	$-25.94M
EPS	—	—	—	—	$-2.24
Free cash flow	$-36.28M	$-37.53M	$-51.89M	$-82.35M	$-28.36M
Profit margin	—	—	—	-896.11%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BIOA	$756.98M	26	4.3	2.5	5.0	9.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

BioAge Labs, Inc trades at $16.85. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 4.81, it sits in the safe zone. TTM revenue stands at $8.99M.

Frequently asked questions

What is BioAge Labs, Inc's stock price?

BioAge Labs, Inc (BIOA) trades at $16.85.

Is BioAge Labs, Inc overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of BioAge Labs, Inc (BIOA)?

The analyst target price is $53.33, representing +216.5% upside from the current price of $16.85.

What is BioAge Labs, Inc's revenue?

TTM revenue is $8.99M.

Piotroski F-Score?

5/9 — moderate financial health.

Altman Z-Score?

4.81 — safe zone.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

bioagelabs.com

Quick metrics

P/S ratio84.16x

ROE-27.10%

Beta—

50D MA$19.01

200D MA$11.57

Shares out0.04B

Float0.04B

Short ratio—

Avg volume0.5M

Performance

1 week+1.16%

1 month-0.29%

3 months-8.69%

YTD+31.82%

1 year—

3 years—

5 years—

Compare

BIOA vs LLY →BIOA vs JNJ →BIOA vs ABBV →Stock screener →